Nurulimab

• Description :

  Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma[1].

• CAS Number :

  [2168561-20-2]

• Product Name Alternative :

  BCD-145

• UNSPSC :

  12352203

• Target :

  CTLA-4

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Immunology/Inflammation

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/nurulimab.html

• Purity :

  95.00

• Solubility :

  10 mM in DMSO

• Smiles :

  [Nurulimab]

• Molecular Weight :

  (143.78 kDa)

• References & Citations :

  [1]International Nonproprietary Names for Pharmaceutical Substances (INN) . WHO Drug Information, Vol. 34, No. 1, 2020.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 1